A citation-based method for searching scientific literature


List of co-cited articles
913 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
55

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
713
31

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
31

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
640
30

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
24

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D Lehmann, Jennifer A Pietenpol, Gabriel N Hortobagyi,[...]. Clin Cancer Res 2013
457
22

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Tiffany A Traina, Kathy Miller, Denise A Yardley, Janice Eakle, Lee S Schwartzberg, Joyce O'Shaughnessy, William Gradishar, Peter Schmid, Eric Winer, Catherine Kelly,[...]. J Clin Oncol 2018
247
21


Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni. Nat Rev Clin Oncol 2016
17

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Ayca Gucalp, Sara Tolaney, Steven J Isakoff, James N Ingle, Minetta C Liu, Lisa A Carey, Kimberly Blackwell, Hope Rugo, Lisle Nabell, Andres Forero,[...]. Clin Cancer Res 2013
440
17

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
17

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
16

The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Sohrab P Shah, Andrew Roth, Rodrigo Goya, Arusha Oloumi, Gavin Ha, Yongjun Zhao, Gulisa Turashvili, Jiarui Ding, Kane Tse, Gholamreza Haffari,[...]. Nature 2012
16

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
H Bonnefoi, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, T L'Haridon, P Cottu, S Abadie-Lacourtoisie, B You,[...]. Ann Oncol 2016
168
14

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
14

Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu. Breast Cancer Res 2020
409
14

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
13

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
Aleix Prat, Barbara Adamo, Maggie C U Cheang, Carey K Anders, Lisa A Carey, Charles M Perou. Oncologist 2013
363
13

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
831
13

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Aleix Prat, Joel S Parker, Olga Karginova, Cheng Fan, Chad Livasy, Jason I Herschkowitz, Xiaping He, Charles M Perou. Breast Cancer Res 2010
12

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
12

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Y Bareche, D Venet, M Ignatiadis, P Aftimos, M Piccart, F Rothe, C Sotiriou. Ann Oncol 2018
164
11

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Brian D Lehmann, Joshua A Bauer, Johanna M Schafer, Christopher S Pendleton, Luojia Tang, Kimberly C Johnson, Xi Chen, Justin M Balko, Henry Gómez, Carlos L Arteaga,[...]. Breast Cancer Res 2014
214
11

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Yi-Zhou Jiang, Ding Ma, Chen Suo, Jinxiu Shi, Mengzhu Xue, Xin Hu, Yi Xiao, Ke-Da Yu, Yi-Rong Liu, Ying Yu,[...]. Cancer Cell 2019
318
11

TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
Brian D Lehmann, Vandana G Abramson, Melinda E Sanders, Erica L Mayer, Tufia C Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R Nangia, Paula I Gonzalez-Ericsson,[...]. Clin Cancer Res 2020
62
17

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Ke-Da Yu, Xi Jin, Xin Hu, Wen-Jia Zuo, Shuang Hao, Jiong Wu, Guang-Yu Liu,[...]. Breast Cancer Res 2016
122
10

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
940
10

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
365
10

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
587
9

Current approaches in treatment of triple-negative breast cancer.
Hanan Ahmed Wahba, Hend Ahmed El-Hadaad. Cancer Biol Med 2015
298
9

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
9

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Lisa A Carey, Hope S Rugo, P Kelly Marcom, Erica L Mayer, Francisco J Esteva, Cynthia X Ma, Minetta C Liu, Anna Maria Storniolo, Mothaffar F Rimawi, Andres Forero-Torres,[...]. J Clin Oncol 2012
356
9

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
Gloria J Morris, Sashi Naidu, Allan K Topham, Fran Guiles, Yihuan Xu, Peter McCue, Gordon F Schwartz, Pauline K Park, Anne L Rosenberg, Kristin Brill,[...]. Cancer 2007
382
9

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko,[...]. Lancet Oncol 2017
282
9

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado,[...]. Lancet 2020
534
9

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
8

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
578
8

Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni. Nat Rev Clin Oncol 2010
597
8

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
8

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
François Bertucci, Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Emilie Mamessier, José Adélaïde, Stéphane Debono, Gilles Houvenaeghel, Dominique Maraninchi, Patrice Viens,[...]. Cancer Res 2006
204
8

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.
Xi Chen, Jiang Li, William H Gray, Brian D Lehmann, Joshua A Bauer, Yu Shyr, Jennifer A Pietenpol. Cancer Inform 2012
171
8

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña,[...]. N Engl J Med 2021
322
8

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Maggie C U Cheang, David Voduc, Chris Bajdik, Samuel Leung, Steven McKinney, Stephen K Chia, Charles M Perou, Torsten O Nielsen. Clin Cancer Res 2008
866
7

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
7


A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Katsuya Nakai, Mien-Chie Hung, Hirohito Yamaguchi. Am J Cancer Res 2016
188
7

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
922
7

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
756
7

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
7

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Valerie N Barton, Nicholas C D'Amato, Michael A Gordon, Jessica L Christenson, Anthony Elias, Jennifer K Richer. Horm Cancer 2015
68
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.